To assess the possible effect of sequencing quality on detection of recombination signals, we performed a recombinant search on IGSP and non-IGSP avian influenza viruses, isolated from birds and humans, similar to the search and analysis in Boni et al. Identification of recombinants is done according to the guidelines defined in this paper. If we assume that the sequences generated through the Influenza Genome Sequencing Project are less likely to be contaminated or to contain fewer sequencing errors because of the rigorous quality control used, then the large number of Oxytetracycline HCl recombination signals present in the non-IGSP data may not reflect the true evolutionary history of these sequences, especially when we note that for some of the longer segments, more than 90–95% of nonIGSP sequences were flagged as recombinant. As viruses sequenced through the IGSP should not recombine more or less frequently than viruses sequenced otherwise, either the non-IGSP recombinants are false positives or we have failed to identify true instances of recombination in the IGSP data sets. As Isoscopoletin 3SEQ has very high power to detect recombination signals, especially in data sets with high nucleotide diversity, it is unlikely that we missed scores or hundreds of recombination signals in the 2197 IGSP sequences considered. The more likely scenario is that the non-IGSP signals are false positives. A growing body of evidence indicates that IL-37 inhibits inflammation reactions in autoimmune diseases, which are commonly associated with disease activities. Our previous evidence indicated that up-regulation of IL-37 mediates a feedback mechanism to suppress pro-inflammatory cytokine productions in patients with SLE. However, the expression and role of IL-37 in GD remain to be elucidated. In this study, we found that IL-37 protein in serum and its mRNA expression levels in PBMCs were significantly higher in GD patients than in HCs. Thus, our results indicated IL-37 involved in the regulation of GD inflammatory reaction. Published data has been demonstrated that IL-37 can alleviate the symptoms of DSS colitis and inflammatory process in psoriasis by inhibiting the expression of inflammatory cytokines in these diseases and reduce liver inflammatory injury via effects on hepatocytes and non-parenchymal cells.